SureTrader Nadex Advertisement
Home > Boards > US Listed > Cannabis >

Zynerba Pharmaceuticals (ZYNE)

ZYNE RSS Feed
Add ZYNE Price Alert      Hide Sticky   Hide Intro
Moderator: djmurdock
Search This Board: 
Last Post: 2/24/2017 9:30:16 AM - Followers: 46 - Board type: Free - Posts Today: 1


Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Company is evaluating approximately two product candidates, ZYN002 and ZYN001, in over five indications. The Company intends to study ZYN002 in patients with refractory epilepsy, osteoarthritis and Fragile X syndrome. The Company's ZYN002 is synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. ZYN002 is being developed as a clear that is designed to provide controlled drug delivery with once- or twice-daily dosing. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through a patch. The Company intends to test the ZYN001 patch for application to the arm, back and thigh. The Company intends to study ZYN001 in patients with fibromyalgia and peripheral neuropathic pain.

Investor Relations

Corporate Profile

Zynerba (NASDAQ: ZYNE) is pioneering the development of patent-protected, next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery. Its two lead product candidates in development include ZYN002 and ZYN001, which are being evaluated in five indications. ZYN002 is the first and only synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. In June 2016, the company initiated the STAR 1 Phase 2 clinical trial in refractory epilepsy patients and in August 2016, initiated the STOP Phase 2 clinical trial in patients with osteoarthritis of the knee. A Phase 2 clinical trial in patients with Fragile X syndrome will be initiated in the second half of 2016. 

ZYN001, a prodrug of THC that enables transdermal delivery through the skin and circulatory system via a patch, is in preclinical development. A Phase 1 clinical trial is planned in the first half of 2017.

In August 2015, Zynerba completed an initial public offering, raising net proceeds of $42.1 million. As of June 30, 2016, cash and cash equivalents totaled $32.1 million, which is projected to fund five Phase 2 clinical trials through 2017.





Zynerba Pharmaceuticals, Inc., (Nasdaq: ZYNE) announced today the pricing of its initial public offering of 3 million shares of common stock at a public offering price of $14.00 per share, before underwriting discounts. All of the shares in the offering are being sold by Zynerba. In addition, Zynerba has granted the underwriters an option to purchase up to 450,000 additional shares of common stock at the public offering price, less the underwriting discount. Zynerba's common stock has been approved for listing on the NASDAQ Global Market and is expected to begin trading under the symbol "ZYNE" on August 5, 2015.

Jefferies LLC and Piper Jaffray & Co. are acting as joint book-running managers for the offering, and Canaccord Genuity Inc. and Oppenheimer & Co. Inc. are acting as co-managers for the offering. This offering is being made only by means of a prospectus.



Extremely low float:

Fundamentals

A table providing the fundamentals of the stock
EPS (TTM) 9/30/2016 | -2.47
P/E Ratio 9/30/2016 | --
Market Cap Micro Cap | 146M
Shares Outstanding 9.95M
Float 7.2M

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ZYNE
Current Price
Volume:
Bid Ask Day's Range
SureTrader
ZYNE News: Amended Statement of Ownership (sc 13g/a) 02/16/2017 02:34:33 PM
ZYNE News: Amended Statement of Ownership (sc 13g/a) 02/15/2017 07:13:13 AM
ZYNE News: Amended Statement of Ownership (sc 13g/a) 02/15/2017 07:10:29 AM
ZYNE News: Amended Statement of Ownership (sc 13g/a) 02/14/2017 06:20:51 PM
ZYNE News: Statement of Ownership (sc 13g) 02/14/2017 06:20:51 PM
PostSubject
#326  Sticky Note Slideshow for new investors djmurdock 12/17/16 05:09:50 PM
#502   Same thing here...trying to reenter low 22's now... CoachMarc 02/24/17 09:30:15 AM
#501   Oh darn, I've been taking profits on this Triple9 02/23/17 11:58:57 PM
#500   Headed to 30$ by eoy imo Cbdpotential 02/23/17 11:43:00 PM
#499   Nice AH :-D Go $ZYNE Cbdpotential 02/23/17 11:42:20 PM
#496   Setting up beautifullly for new highs. a surfer 02/22/17 09:33:16 PM
#495   Another strong day! Holding tight. djmurdock 02/22/17 10:28:18 AM
#494   Great sign there my friend. We do not WolfOfGrnStreet 02/21/17 10:57:27 PM
#493   More institutional buying djmurdock 02/21/17 01:52:46 PM
#492   Thanks a ton--I always learn something when you Pugetsounder1 02/20/17 11:43:52 AM
#490   To be approved as an index tracking fund Triple9 02/19/17 11:30:31 PM
#489   T9, how do u think the ETF will Pugetsounder1 02/19/17 10:56:28 PM
#487   Representatives Dana Rohrabacher (CA-48), Earl Blumenauer (OR-03), Don Triple9 02/16/17 08:02:12 PM
#486   Did you know there's a MMJ Index called Triple9 02/16/17 05:32:18 PM
#485   Can't stop the $zyne train! Chuga chuga chuga djmurdock 02/16/17 02:42:17 PM
#484   GREEN! What a comeback! Roaring ZYNE! CoachMarc 02/16/17 02:04:14 PM
#483   A green close today would be very bullish. djmurdock 02/16/17 01:14:32 PM
#482   No sure what the close will be like, CoachMarc 02/16/17 01:06:46 PM
#481   http://www.marketwatch.com/story/harry-boxer-these-four-momentum-stocks-are-brea djmurdock 02/16/17 02:22:12 AM
#480   It's anyone's guess but it is very strong. WolfOfGrnStreet 02/15/17 08:36:46 PM
#479   U bet. I agree in that buying now devilmafia 02/15/17 08:30:06 PM
#478   Shorters ***beware*** we head to $25 in the WolfOfGrnStreet 02/15/17 08:20:24 PM
#477   I've managed to increase my holdings from June a surfer 02/15/17 05:50:57 PM
#476   IMHO this will be back at it's IPO djmurdock 02/15/17 04:04:59 PM
#475   Which still is lower than GWPH markets cap!!! eskay1954 02/15/17 03:36:01 PM
#474   This is a stock you buy and do eskay1954 02/15/17 03:34:52 PM
#473   Great advice!! Out 1k at 23.36 Ready at a surfer 02/15/17 01:50:03 PM
#471   I really hope shorts get burnt and we WolfOfGrnStreet 02/15/17 08:19:12 AM
#470   Looks Ike Cara early this week. Cara took acrazjo 02/14/17 08:44:15 PM
#469   RSI at hot at 74. Probably needs to CoachMarc 02/14/17 01:08:47 PM
#468   Beast mode! djmurdock 02/14/17 12:54:44 PM
#467   30s by next month if not sooner. Loving WolfOfGrnStreet 02/14/17 12:02:50 PM
#466   This looks hell bent on upper 20's soon!! a surfer 02/14/17 11:09:09 AM
#465   Over 5% again!!! a surfer 02/14/17 11:09:08 AM
#464   Getting more love on valentines day!! NICE!!!! a surfer 02/14/17 10:53:30 AM
#463   Almost at the high of the day too, djmurdock 02/13/17 04:11:35 PM
#462   $21.24....You got it! Heading to 24-26 range now! CoachMarc 02/13/17 04:06:20 PM
#461   A close above $21 will be a very djmurdock 02/13/17 03:56:24 PM
#460   Love it $ZYNE Cbdpotential 02/13/17 11:43:11 AM
#459   No doubt. This is a great hold devilmafia 02/13/17 10:42:50 AM
#458   Perfect storm. Hold tight. These next a surfer 02/13/17 10:38:55 AM
#457   $ZYNE$ heading for a blue sky breakout surfgreen 02/13/17 10:22:51 AM
#456   It only gets better WolfOfGrnStreet 02/10/17 07:31:03 PM
#455   (: Zyne is my biggest holding currently. djmurdock 02/10/17 03:38:37 PM
#454   We have a winner here. I have a surfer 02/10/17 03:20:19 PM
#453   Good call! CoachMarc 02/10/17 03:19:04 PM
#452   Hiccup over eskay1954 02/10/17 02:44:02 PM
#451   Looks like we'll be breaking $20 again very djmurdock 02/10/17 02:16:20 PM
#450   Me too Cbdpotential 02/08/17 01:10:48 PM
#449   Ha! No doubt - luv this stock. Chart surfgreen 02/07/17 06:56:07 PM
#448   It's going to run again WolfOfGrnStreet 02/07/17 06:53:59 PM
PostSubject